Recent news on Interferon Beta-1A

New Formulation Interferon Beta-1a Demonstrates Improved Safety ...  -  May 8, 2007
DG NewsBOSTON, MA -- May 8, 2007 -- One-year results of a Phase 3b trial of the new formulation interferon beta-1a (Rebif New Formulation; RNF) demonstrate an

Hatching hep C hope  -  May 9, 2007
BiopharmaReporter.com,...for example, have already suggested that a single flock of a few hundred birds could satisfy the entire US market demand for interferon beta-1a.

Biogen Idec Reports First Quarter 2007 Results  -  May 2, 2007
Genetic Engineering News (press release),First quarter revenues were $716 million, an increase of 17% from $611 million in the prior year, driven primarily by AVONEX(R) (interferon beta-1a) sales

Biogen Idec Launches New Avonex® Nurse Services Program  -  Apr 30, 2007
Medical News Today (press release),Biogen Idec (NASDAQ: BIIB) announced today the national launch of the new AVONEX® (Interferon beta-1a) Nurse Services program which is designed to help

Biogen Idec Launches New Avonex Nurse Services Program  -  Apr 26, 2007
PharmaLive.com (press release),CAMBRIDGE, MA - April 26, 2007- Biogen Idec (NASDAQ: BIIB) announced today the national launch of the new AVONEX® (Interferon beta-1a) Nurse Services

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year ...  -  May 8, 2007
Oxfordshire Bioscience Network (press release),...the sustained accumulation of disability in early active relapsing remitting multiple sclerosis (RRMS) patients compared to Rebif® (interferon beta-1a).

Biogen Idec/Genentech: Promising phase II data for rituximab in MS  -  May 1, 2007
Pharmaceutical Business ReviewMoreover, through the marketing of Avonex (interferon beta 1a) and Tysabri (natalizumab), Biogen Idec is well placed to drive uptake among prescribers.

Biogen Idec Launches New Avonex Nurse Services Program  -  26 Apr 2007
PharmaLive.com (press release),CAMBRIDGE, MA - April 26, 2007- Biogen Idec (NASDAQ: BIIB) announced today the national launch of the new AVONEX® (Interferon beta-1a) Nurse Services

Serono acquisition sends Merck KGaA into the red  -  26 Apr 2007
Pharma Times (subscription),...drug Erbitux which jumped 48% to 110 million euros, while the multiple sclerosis treatment Rebif (interferon beta-1a) rose 3.5% to 283 million euros.

NEW PHARMACOECONOMIC STUDY SHOWS AVONEX® IS COST-EFFECTIVE FOR ...  -  Apr 13, 2007
WebWire (press release),...patients on interferon beta therapy were: AVONEX, $19896.15; Rebif® (Interferon beta-1a) sc, $22207.85; and Betaseron® (Interferon beta-1b), $21073.33.

Large Study Shows that Presence of Neutralizing Antibodies Do Not ...  -  Apr 3, 2007
WebWire (press release),Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre

Clinical Manifestations of Childhood Multiple Sclerosis  -  Mar 1, 2007
AAP Grand Rounds (subscription),Of 9 patients receiving periodic, subcutaneous interferon beta-1a, 4 (44%) had no relapses. The course was relapsing/remitting in 86% and progressive in 14%

Merck KGaA is delighted as Serono earnings soar  -  Mar 1, 2007
Pharma Times (subscription),For the full year, Rebif (interferon beta-1a) sales were up 14% to $1.45 billion, and up 26% in the USA to $493 million, despite increasing competition in

Medical Edge: Plasma exchange used as treatment, not cure, for MS  -  Jan 27, 2007
Bryan College Station Eagle,The best known among them are interferon beta-1b (Betaseron) and interferon beta-1a (Avonex, Rebif), which are genetically engineered copies of proteins

Biogen has high hopes for Tysabri's future as earnings soar  -  Feb 16, 2007
Pharma Times (subscription),Sales of Avonex (interferon beta-1a) increased 6% to $439 million and revenues from Rituxan (rituximab), which come from Biogen's joint venture with

Biogen Idec Increases Profits But Misses 4Q EPS Estimates  -  Feb 15, 2007
BioWorld Online,The perception that sales are lagging for its flagship product, the multiple sclerosis drug Avonex (interferon beta-1a), played a role in investors' jitters

Biogen Idec Reports Full Year and Fourth Quarter 2006 Results  -  Feb 15, 2007
WebWire (press release),...joint business arrangement, which were up 14% to $811 million and AVONEX® (interferon beta-1a) sales, which increased 11% to $1.71 billion.

Therapeutic protein production in chicken eggs  -  Jan 17, 2007
WorldPoultry.net,It has previously been estimated that a small flock of a few hundred hens could satisfy the entire US market demand for interferon beta-1a.

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),...were released in September and showed a robust, statistically significant treatment effect for alemtuzumab compared with Rebif® (interferon beta-1a).

Generics unit may be sold as Merck Serono is launched  -  Jan 8, 2007
Pharma Times (subscription),...euros and "the two key growth drivers," the colorectal cancer drug Erbitux (cetuximab) and the multiple sclerosis treatment Rebif (interferon beta-1a).

I've been told that I have MS. What course will it take?  -  Dec 21, 2006
Times Online,Currently the treatment of choice is Interferon beta-1a or 1b. Both reduce the severity of the relapses and their frequency. A new drug Tysabri,

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  Dec 12, 2006
Drug Newswire (press release),Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta

Diagnosis and Monitoring of Multiple Sclerosis: Focus on ...  -  Nov 27, 2006
Medscape (subscription)The MRI T2 burden of interferon beta-1a given 30 micrograms (mcg) intramuscularly weekly vs 44 mcg subcutaneously thrice weekly was studied in a post hoc

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)The Safety and Efficacy of Natalizumab in Combination with Avonex (interferon beta-1a) (SENTINEL) trial is an example of add-on therapy because natalizumab

I've been told that I have MS. What course will it take?  -  Dec 21, 2006
Times Online,Currently the treatment of choice is Interferon beta-1a or 1b. Both reduce the severity of the relapses and their frequency. A new drug Tysabri,

Novartis Highlights Strong R&D Pipeline, Plans For Multiple New ...  -  Nov 29, 2006
Medical News Today (press release),A one-year trial (TRANFORMS) started in May 2006 comparing FTY720 with interferon beta-1a (Avonex®). Two-year data from the extension of a Phase II trial

Schering's Campath reports promising first-line Ph III data  -  Dec 12, 2006
Pharma Times (subscription),...was seen to be excellent, cutting the relapse rate in patients by 75% compared to the comparator drug, Serono's blockbuster Rebif (interferon beta-1a).

St. Elizabeth's starts palliative care program  -  Dec 5, 2006
Belleville News-Democrat,Study participants will be randomly divided into three groups: A fourth will received Interferon beta-1a (Avonex), a fourth will be given Copaxone and half

Research and Markets: Richter is One of the Last Major CEE ...  -  Nov 27, 2006
PharmaLive.com (press release),Its largest distributed product is Avonex (interferon beta-1a), which it sells for Biogen in a number of CEE markets. Richter is one of the last major CEE

AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy ...  09 Nov 2006
Therapy to Japanese MS Community CAMBRIDGE, MASS., November 8 /CNW/ - Biogen Idec (NASDAQ: BIIB) announced today that AVONEX(R) (Interferon beta-1a), the most ... -CNW Telbec (Communiqués de presse), MS Patients Benefit From Interferon  Oct 8, 2006
...disease. New research from Switzerland reveals interferon beta-1a can help patients who have the relapsing-remitting type of MS. ... -Ivanhoe, Multiple sclerosis treatment: Is combination therapy effective?  Nov 2, 2006
Interferon beta-1a (Avonex, Rebif) and glatiramer (Copaxone) are two drugs approved by the Food and Drug Administration for the treatment of relapsing ... -MayoClinic.com Biogen Idec Reports Third Quarter 2006 Results  Oct 31, 2006
...prior year of $596 million, an increase of 18%, driven primarily by AVONEX(R) (Interferon beta-1a) worldwide sales up 19% to $445 million and RITUXAN(R ... -Genetic Engineering News (press release), Biogen Idec Reports Third Quarter 2006 Results  Oct 31, 2006
...prior year of $596 million, an increase of 18%, driven primarily by AVONEX® (Interferon beta-1a) worldwide sales up 19% to $445 million and RITUXAN ... -WebWire (press release), Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
2 study were released in September and showed a robust, statistically significant treatment effect for alemtuzumab compared with Rebif® (interferon beta-1a). ... -Yahoo! News (press release) AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide ...  Oct 20, 2006
AVONEX(R) (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be stored at room temperature (up to 77 degrees F or 25 ... -Genetic Engineering News (press release), Avonex, The #1 Prescribed Multiple Sclerosis Therapy Worldwide ...  Oct 20, 2006
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 20, 2006 - AVONEX(R) (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be ... -PharmaLive.com (press release), AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide ...  Oct 20, 2006
AVONEX® (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be stored at room temperature (up to 77°F or 25°C ... -International News Service, AVONEX ® , The #1 Prescribed Multiple Sclerosis Therapy Worldwide ...  Oct 20, 2006
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVONEX ® (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be stored at room ... -Business Wire (press release), Multiple sclerosis: Campath more effective than Rebif  Sep 17, 2006
Two-year interim results from a Phase 2 trial comparing Campath ( Alemtuzumab ) with Rebif ( Interferon beta-1a ) for the treatment of multiple sclerosis have ... -Xagena.it

Genzyme Reports Interim Results from Trial of Campath(R) for ...  Sep 14, 2006
Nasdaq: GENZ) today announced two-year interim results from a Phase 2 trial comparing Campath(R) (alemtuzumab) with Rebif(R) (interferon beta-1a) for the ... -PR Newswire

Merck KGaA Buying Serono, Giving CHF16.6B Valuation  Sep 21, 2006
...capability to the enlarged entity, Serono is supplying it with its two biggest sellers, the multiple sclerosis drug Rebif (interferon beta-1a), which generated ... -BioWorld Online

World News | Merck to buy Serono in $13.5bn deal - 21/09/2006  Sep 21, 2006
Serono brings its multiple sclerosis drug Rebif (interferon beta-1a) to the table, with Merck contributing fast-growing cancer treatment Erbitux (cetuximab). ... -Pharma Times (subscription)

TODAY ON PHARMALIVE.COM  Sep 12, 2006
Neither treatment with Avonex(R) (Interferon beta-1a IM) nor Betaseron(R) (Interferon beta-1b) was associated with significantly fewer days missed from work in ... -PharmaLive.com

Genzyme sees solid data on MS drug  Sep 14, 2006
The company said two-year data from a phase 2 study comparing Campath with the interferon beta-1a drug Rebif for MS showed that patients taking alemtuzumab at ... -United Press International

Genzyme (GENZ) Announces Phase II Trial Comparing Campath with ...  Sep 14, 2006
...at least a 75 percent reduction in the risk for relapse after at least two years of follow up when compared to patients treated with interferon beta-1a. ... -StreetInsider.com (subscription)

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  12 Dec 2006
Drug Newswire (press release),Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta

Schering's Campath reports promising first-line Ph III data  -  12 Dec 2006
Pharma Times (subscription),...was seen to be excellent, cutting the relapse rate in patients by 75% compared to the comparator drug, Serono's blockbuster Rebif (interferon beta-1a).

Diagnosis and Monitoring of Multiple Sclerosis: Focus on ...  -  Nov 27, 2006
Medscape (subscription)The MRI T2 burden of interferon beta-1a given 30 micrograms (mcg) intramuscularly weekly vs 44 mcg subcutaneously thrice weekly was studied in a post hoc

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)The Safety and Efficacy of Natalizumab in Combination with Avonex (interferon beta-1a) (SENTINEL) trial is an example of add-on therapy because natalizumab

Avonex®, The Most Prescribed Multiple Sclerosis Therapy Worldwide ...  -  Nov 23, 2006
Medical News Today (press release),Biogen Idec (NASDAQ: BIIB) announced today that AVONEX® (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide,

St. Elizabeth's starts palliative care program  -  Dec 5, 2006
Belleville News-Democrat,Study participants will be randomly divided into three groups: A fourth will received Interferon beta-1a (Avonex), a fourth will be given Copaxone and half

Novartis Highlights Strong R&D Pipeline, Plans For Multiple New ...  -  Nov 29, 2006
Medical News Today (press release),A one-year trial (TRANFORMS) started in May 2006 comparing FTY720 with interferon beta-1a (Avonex®). Two-year data from the extension of a Phase II trial

Research and Markets: Richter is One of the Last Major CEE ...  -  Nov 27, 2006
PharmaLive.com (press release),Its largest distributed product is Avonex (interferon beta-1a), which it sells for Biogen in a number of CEE markets. Richter is one of the last major CEE

Serono Announces Results From Pivotal Phase III Clinical Trial of ...  Aug 17, 2006
The Company has seven recombinant products, Rebif(R) (interferon beta-1a), Gonal-f(R) (follitropin alfa for injection), Luveris(R) (lutropin alfa), Ovidrel ... -PR Newswire

Get the latest news direct to your desktop  Aug 18, 2006
The Company has seven recombinant products, Rebif® (interferon beta-1a), Gonal-F® (follitropin alfa for injection), Luveris® (lutropin alfa), Ovidrel ... -PipelineReview.com

Why are doctors so reluctant to prescribe treatment for MS?  Aug 3, 2006
The immuno modulators Avonex (interferon beta 1a), Betaferon (interferon beta 1b) and Copaxone (glatiramer) are drugs that reduce the frequency and severity of ... -Times Online

DGAP-News: STADA: Strong growth continues in H1/2006 - sales +18% ...  Aug 9, 2006
In the context of the development of the biosimilar products Erythropoietin, Filgrastim and Interferon beta-1a which is being carried out by BIOCEUTICALS ... -Financial.de

European Commission approves revision of therapeutic indication ...  Aug 7, 2006
SRA) announced that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) of Rebif (interferon beta-1a), in order to ... -Therapeutics Daily (subscription)

Biogen Idec Reports Second Quarter 2006 Results  Jul 26, 2006
...prior year $606 million, an increase of 9%, driven primarily by AVONEX(R) (Interferon beta-1a) worldwide sales up 12% to $429 million and RITUXAN(R) (rituximab ... -Finanzen.net

European Commission Approves Revision of Therapeutic Indication ...  Jul 10, 2006
...announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) of Rebif(R) (interferon beta-1a), in order ... -DG News

Delivers Solid Earnings Growth Based on Strong Top-Line ...  Jul 18, 2006
...patients have now completed at least 24 months in the ongoing Phase 2 clinical trial comparing alemtuzumab with Rebif® (interferon beta-1a) for the treatment ... -Oxfordshire Bioscience Network

European Commission Approves Revision of Therapeutic Indication ...  Jul 9, 2006
...announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) of Rebif® (interferon beta-1a), in order ... -Yahoo! News

European Commission Approves Serono's SmPC Update For Multiple ...  Jul 9, 2006
Now, Rebif or interferon beta-1a can be prescribed throughout the European Union after confirming MS, based on one attack and subsequent positive magnetic ... -Trading Markets

Serono's Rebif Receives European Commission Approval For Revision ...  Jul 9, 2006
PowerRating) reported that European Commission approved an update of the Summary of Product Characteristics or SmPC of Rebif or interferon beta-1a, in order to ... -Trading Markets

COPAXONE(R) Reduced Relapses By 75 Percent in Both Treatment-Naive ...  Jun 20, 2006
...study published in June 2006 in the European Journal of Neurology, where data showed that patients who switched from Avonex(R) (interferon beta-1a) to COPAXONE ... -PR Newswire

DGAP-News: STADA: Approval documents for Erythropoietin biosimilar ...  Jun 29, 2006
In addition to Erythropoietin-zeta, the company is also carrying out development on two biosimilars from Filgrastim and Interferon beta-1a. ... -Financial.de



Teva: Copaxone on the up  Apr 7, 2006
...approved, the new dose would strengthen Copaxone's standing against its rivals in the MS market, including Pfizer's Rebif (interferon beta-1a), Biogen Idec's ... - Pharmaceutical Business Review

Combination Appears Safe in Relapsing-Remitting Multiple Sclerosis ...  Apr 4, 2006
...of the addition of azathioprine to intramuscular interferon beta 1-a in patients who were incompletely responsive to intramuscular interferon beta-1a and to ... - DG News

New Tysabri® Data Demonstrate Significant Effects On Health ...  Apr 8, 2006
Improvements on quality of life measures were also observed in the SENTINEL study, in which TYSABRI was added to AVONEX® (Interferon beta-1a). ... - Medical News Today

Astellas snaps up Biogen Idec's Amevive  Apr 5, 2006
Meanwhile, Biogen Idec says new data show its big-selling MS therapy Avonex (interferon beta-1a) effectively delays the development of so-called clinically ... - Pharma Times (subscription)

Research Notes The Effectiveness of Controversial Multiple ...  Mar 9, 2006
Researchers are reporting that when used in combination with the standard treatment of interferon beta-1a, natalizumab, the drug previously marketed under the ... - eMaxHealth.com

Wonder drugs don’t exist for MS; stick with proven options  Mar 26, 2006
Interferon beta-1b (Betaseron), interferon beta-1a (Avonex, Rebif), glatiramer (Copaxone), and mitoxantrone (Novantrone) are only partially effective in the ... - Fort Wayne Journal Gazette

Protein lab test could spot MS early  Mar 14, 2006
Interferon beta-1a (Avonex or Rebif) and interferon beta-1b (Betaferon) are used for some people who have the relapsing and remitting form of the disease. ... - LabTechnologist.com

Tysabri should return to market, says FDA panel  Mar 9, 2006
The panel also said the drug should not be used in combination with other MS drugs, such as Biogen Idec's own Avonex (interferon beta-1a), Serono's Rebif ... - Pharma Times (subscription)

Advisory Committee Recommends Tysabri Return  Mar 14, 2006
...of deaths from progressive multifocal leukoencephalopathy, a rare brain disease, when taken in conjunction with another MS drug, Avonex (Interferon beta-1a). ... - PharmExec.com

Q&A: Biogen's Multiple Sclerosis Drug Tysabri  Mar 8, 2006
Both patients were receiving Avonex (interferon beta-1a), another approved treatment for MS, at the same time that they were being treated with Tysabri. ... - Food Consumer

Tysabri sales and sclerosis drug  Mar 8, 2006
Data from the Phase III AFFIRM monotherapy trial, the Phase III SENTINEL trial in which TYSABRI was added to AVONEX (Interferon beta-1a) therapy, and the ... - Actualités News Environnement

FDA Advisers Urge a Second Chance for Tysabri  Mar 8, 2006
In a second study, Tysabri in combination with Avonex (interferon beta-1a) was significantly more effective than Avonex alone at preventing relapses over two ... - MedPage Today



Do Over: New MS drug may be safe after all  Mar 3, 2006
Together, these tests included 1,859 MS patients. In the US study, all patients also received interferon-beta 1a, a current MS drug. ... - Science News

This Week in Health  Mar 3, 2006
Two of the new studies looked at Tysabri's effectiveness, alone or in combination with interferon beta-1a, in a combined total of over 2,000 MS patients. ... - Intelihealth.com,

Studies Suggest Controversial Multiple Sclerosis Drug Is Safe  Mar 1, 2006
...disease. The second trial found that, when combined with interferon beta-1a, Tysabri reduced the risk of relapse by 55 percent. ... - Forbes

Tysabri lurches on towards pivotal March meeting  Mar 2, 2006
Likewise, for Biogen Idec the drug was intended to bolster the firm's MS franchise as its Avonex (interferon beta-1a) product started feeling the effects of ... - Pharma Times (subscription),

Biogen Idec Reports Full Year and Fourth Quarter 2005 Results  Feb 15, 2006
...by RITUXAN(R) (rituximab) revenues from the unconsolidated joint business arrangement up 15% to $709 million and AVONEX(R) (Interferon beta-1a) sales up 9% to ... - Genetic Engineering News,

Flat sales in Q4 for Serono; no word on buyer  Feb 6, 2006
The Swiss biotechnology company, which put itself up for sale last year but has yet to find a buyer, said top-selling product Rebif (interferon beta-1a) grew 8 ... - Pharma Times (subscription),

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional